Medical Condition News

RSS

Research opens door to new prostate cancer treatment

Researchers from the Centenary Institute’s Origins of Cancer Program have discovered new links between nutrition and prostate cancer.

26 Mar 2015

AstraZeneca, HSCI collaborate to find new treatments for diabetes

AstraZeneca today announced that it has entered into a five-year research collaboration with the Harvard Stem Cell Institute to adapt a technique that creates human beta cells from stem cells for use in screens of AstraZeneca’s compound library in the search for new treatments for diabetes.

26 Mar 2015

New Quest Diagnostics study analyses impact of ACA in promoting earlier diagnosis of diabetes

People in states that expanded Medicaid under the Affordable Care Act (ACA) are far more likely to be newly identified with diabetes than in states that elected not to expand the public health care program, finds a new study by researchers at Quest Diagnostics.

From Quest Diagnostics 26 Mar 2015

BeyondSpring files two patent applications to expand therapeutic scope of Plinabulin

BeyondSpring Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, today announced that it has filed two new method of treatment patent applications with the United States Patent and Trademark Office to cover methods of treating brain tumors as well as cancers expressing a mutant form of RAS protein through administration of the Company’s lead compound, Plinabulin.

26 Mar 2015

Novasep, Celladon sign agreement to develop and supply MYDICAR drug substance

Novasep, a leading supplier of services and technologies for the life sciences and chemical industries, and Celladon Corporation, a clinical-stage cardiovascular gene therapy company, today announce that they have signed a Development, Manufacturing and Supply Agreement pursuant to which, if supported by upcoming MYDICAR clinical data, Novasep would manufacture MYDICAR drug substance through 2018 with extension options through 2020.

26 Mar 2015

Arno Therapeutics' AR-42 with cisplatin demonstrates anti-tumor effect in bladder cancer models

Arno Therapeutics, Inc., a clinical stage biopharmaceutical company primarily focused on the development of oncology therapeutics, today announced that data from a preclinical study demonstrate its histone-deacetylase (HDAC) inhibitor AR-42 in combination with cisplatin has a synergistic anti-tumor effect in bladder cancer models.

26 Mar 2015

Theravectys gets authorization to produce lentiviral vectors for clinical use and CAR-T cell-based immunotherapy

THERAVECTYS, a clinical development biotechnology company that focuses on the development of therapeutic vaccines and immunotherapies, proudly announces that its manufacturing plant has obtained the status of a pharmaceutical manufacturing establishment, granted by the French National Agency for Medicines and Health Products Safety.

26 Mar 2015

TSRI scientists identify enzyme that maintains healthy periods of inactivity in HSCs to prevent anemia

Stem cells can generate any type of cell in the body, but they are inactive most of the time—and for good reason. When stem cells become too active and divide too often, they risk acquiring cell damage and mutations. In the case of blood stem cells (also called hematopoietic stem cells or HSCs), this can lead to blood cancers, a loss of blood cells and an impaired ability to fight disease.

26 Mar 2015

Agena Bioscience releases LungFUSION Panel to identify gene fusions in NSCLC tumors

Agena Bioscience today released the LungFUSION Panel for rapid and sensitive identification of oncogenic ALK, RET, and ROS1 gene fusions in non-small cell lung cancer tumors.

25 Mar 2015

Regulus' RG-012 receives orphan medicinal product designation in EU for treatment of Alport syndrome

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that the European Commission has granted orphan medicinal product designation for RG-012, a single stranded, chemically modified oligonucleotide that binds to and inhibits the function of microRNA-21 ("miR-21") for the treatment of Alport syndrome, a life-threatening genetic kidney disease with no approved therapy.

25 Mar 2015

TVA Medical's novel hemodialysis access technique shows positive outcomes in clinical study

TVA Medical, Inc., today announced promising results from a clinical study evaluating a novel hemodialysis access technique that has the potential to revolutionize vascular access for patients with chronic kidney disease without the use of traditional open surgery.

25 Mar 2015

IV cosyntropin therapy matches EBP in relieving pain from post-dural puncture headache

Intravenous (IV) cosyntropin therapy was equivalent to epidural blood patch (EBP) in relieving pain from post-dural puncture headache (PDPH) with potential for fewer complications and lower costs, data from a randomized, controlled trial showed.

25 Mar 2015

Qualcomm Life, AMC Health to accelerate transformation of health care delivery for at-risk patients

Qualcomm Life, Inc., a subsidiary of Qualcomm Incorporated, and AMC Health, a privately held provider of 'real-time' patient management solutions, today announced a collaborative effort to accelerate the transformation of chronic care and population health management by significantly enhancing connectivity and care coordination for at-risk patients, specifically those with heart failure, hypertension, diabetes, asthma or COPD, in a cost-effective manner.

25 Mar 2015

Personalized gene therapy to fight against cancer

The fight to treat cancer and eradicate tumors will likely benefit from a new set of treatments if early development phases continue to show promise, according to Kalorama Information. The healthcare market research publisher stated that gene therapies that are able to deliver genetic material to a specific cell population or tumor that will result in the destruction of the tumor.

25 Mar 2015

DCR representatives to present health-related quality posters at NKF's 2015 Spring Clinical Meeting

DaVita Clinical Research, a specialty contract research organization with services spanning the full spectrum of drug and device development and subsidiary of DaVita HealthCare Partners Inc., today announced that company representatives will present health-related quality posters at National Kidney Foundation's 2015 Spring Clinical Meeting, which takes place March 25-29, 2015 in Dallas.

25 Mar 2015

Serious head injuries may contribute to faster brain ageing, new study reveals

People who have suffered serious head injuries show changes in brain structure resembling those seen in older people, according to a new study.

25 Mar 2015

Study: Blood test can help identify bowel cancer patients who may benefit from chemotherapy

Manchester researchers have provided early evidence to suggest that a blood test could be used to identify bowel cancer patients that may benefit from more intensive chemotherapy.

25 Mar 2015

New AGA guideline changes clinical practice for patients with asymptomatic pancreatic cysts

A new guideline from the American Gastroenterological Association changes clinical practice by recommending longer surveillance periods for patients with asymptomatic pancreatic cysts and new criteria that limits surgery to those who will receive the most benefit.

25 Mar 2015

New study reveals how cells sort out loops meant to encode microRNAs

Just as two DNA strands naturally arrange themselves into a helix, DNA's molecular cousin RNA can form hairpin-like loops. But unlike DNA, which has a single job, RNA can play many parts -- including acting as a precursor for small molecules that block the activity of genes. These small RNA molecules must be trimmed from long hairpin-loop structures, raising a question: How do cells know which RNA loops need to be processed this way and which don't?

25 Mar 2015

Egalet announces plans to commercialize SPRIX Nasal Spray and OXAYDO tablets

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced its plans for the commercialization of SPRIX (ketorolac tromethamine) Nasal Spray and OXAYDO (oxycodone HCI, USP) tablets for oral use only –CII.

25 Mar 2015

Medical Condition News

Research opens door to new prostate cancer treatment

AstraZeneca, HSCI collaborate to find new treatments for diabetes

New Quest Diagnostics study analyses impact of ACA in promoting earlier diagnosis of diabetes

BeyondSpring files two patent applications to expand therapeutic scope of Plinabulin

Novasep, Celladon sign agreement to develop and supply MYDICAR drug substance

Arno Therapeutics' AR-42 with cisplatin demonstrates anti-tumor effect in bladder cancer models

Theravectys gets authorization to produce lentiviral vectors for clinical use and CAR-T cell-based immunotherapy

TSRI scientists identify enzyme that maintains healthy periods of inactivity in HSCs to prevent anemia

Agena Bioscience releases LungFUSION Panel to identify gene fusions in NSCLC tumors

Regulus' RG-012 receives orphan medicinal product designation in EU for treatment of Alport syndrome

TVA Medical's novel hemodialysis access technique shows positive outcomes in clinical study

IV cosyntropin therapy matches EBP in relieving pain from post-dural puncture headache

Qualcomm Life, AMC Health to accelerate transformation of health care delivery for at-risk patients

Personalized gene therapy to fight against cancer

DCR representatives to present health-related quality posters at NKF's 2015 Spring Clinical Meeting

Serious head injuries may contribute to faster brain ageing, new study reveals

Study: Blood test can help identify bowel cancer patients who may benefit from chemotherapy

New AGA guideline changes clinical practice for patients with asymptomatic pancreatic cysts

New study reveals how cells sort out loops meant to encode microRNAs

Egalet announces plans to commercialize SPRIX Nasal Spray and OXAYDO tablets

A new method to measure intracellular water in biological systems

Obesity, GLP-1s, and metabolic care

Automation in cell-based workflows

Latest News